Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration

About this resource:

Systematic Review

Source: The Cochrane Collaborative

Last Reviewed: March 2019

Workgroups: Vision Workgroup

In this Cochrane systematic review, the Cochrane Collaborative found that anti‐vascular endothelial growth factor (anti‐VEGF) medicines — pegaptanib, ranibizumab and bevacizumab — improve vision and reduce vision loss in people with neovascular age‐related macular degeneration (wet AMD). People treated with anti-VEGF medicines also had improvements in eye structure. In addition, researchers found that participants who took ranibizumab or bevacizumab for at least 1 year had similar vision outcomes. The main difference between treatments was cost (bevacizumab was cheaper), and very few serious side effects occurred. 

Read more about this resource

Objectives related to this resource (1)

Reduce vision loss from age-related macular degeneration — V‑07
Baseline only

Suggested Citation

1.

Solomon, S. D., Lindsley, K., Vedula, S. S., Krzystolik, M. G., & Hawkins, B. S. (2014). Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews, 2014 (8). DOI: 10.1002/14651858.CD005139.pub4.